Keyword Analysis & Research: biogen
Keyword Research: People who searched biogen also searched
Search Results related to biogen on Search Engine
-
Home | Biogen
https://www.biogen.com/
Web ResultBiogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity …
DA: 20 PA: 80 MOZ Rank: 24
-
Company | Biogen
https://www.biogen.com/company.html
Web ResultBiogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity …
DA: 43 PA: 1 MOZ Rank: 25
-
Pipeline | Biogen
https://www.biogen.com/science-and-innovation/pipeline.html
Web ResultBreaking New Ground With Science. With a strong focus on difficult-to-treat diseases, our pipeline is focused on research in therapeutic areas where we believe we have the best opportunity to deliver transformational medicines to …
DA: 54 PA: 96 MOZ Rank: 89
-
Biogen - Wikipedia
https://en.wikipedia.org/wiki/Biogen
Web ResultBiogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, …
DA: 41 PA: 89 MOZ Rank: 17
-
Biogen Inc. (BIIB) Stock Price, News, Quote & History - Yahoo Finance
https://finance.yahoo.com/quote/BIIB/
Web ResultBiogen Inc. (BIIB) closed the most recent trading day at $216.69, moving -0.65% from the previous trading session. Zacks Labcorp (LH) Boost Diagnostics Suite With New …
DA: 29 PA: 7 MOZ Rank: 54
-
Biogen | Investor Relations
https://investors.biogen.com/
Web ResultMar 6, 2024 · Founded in 1978, Biogen is a leading global biotechnology company that has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of …
DA: 63 PA: 43 MOZ Rank: 83
-
Multiple Sclerosis | Biogen
https://www.biogen.com/disease-areas/multiple-sclerosis.html
Web ResultAs pioneers in neuroscience, Biogen has an innovative therapeutic pipeline that aims to reverse disability, repair damage, and address other remaining unmet needs in MS, with the goal of significantly altering the course of MS and preventing disease development and disability progression.
DA: 37 PA: 27 MOZ Rank: 19
-
FDA Approves LEQEMBI™ (lecanemab-irmb) Under the Accelerated ... - Biogen
https://investors.biogen.com/news-releases/news-release-details/fda-approves-leqembitm-lecanemab-irmb-under-accelerated-approval
Web ResultBiogen to Participate in the Stifel 2024 Virtual CNS Days. Cambridge, MA, - - Biogen Inc (Nasdaq: BIIB) announced today that Priya Singhal, M.D., M.P.H., Head of Development, will participate in a fireside chat during the Stifel 2024 Virtual CNS Days. The webcast will be live on Tuesday, March 19, 2024, at 10:00 a.m. ET.
DA: 67 PA: 29 MOZ Rank: 39
-
FDA Grants Accelerated Approval for QALSODY™ (tofersen) for ... - Biogen
https://investors.biogen.com/news-releases/news-release-details/fda-grants-accelerated-approval-qalsodytm-tofersen-sod1-als
Web ResultCAMBRIDGE, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today that the U.S. Food and Drug Administration (FDA) has approved QALSODY™ (tofersen) 100 mg/15mL injection for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 ( SOD1) …
DA: 60 PA: 33 MOZ Rank: 86
-
FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a …
https://investors.biogen.com/news-releases/news-release-details/fda-approves-biogens-tofidencetm-tocilizumab-bavi-biosimilar
Web ResultSep 29, 2023 · CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved TOFIDENCE (tocilizumab-bavi) intravenous formulation, a biosimilar monoclonal antibody referencing ACTEMRA. The TOFIDENCE intravenous …
DA: 45 PA: 97 MOZ Rank: 10